We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 14, 2022

Real-World Incidence and Management of AEs in Patients With HR+, HER2− Metastatic Breast Cancer Receiving CDK4/6 Inhibitors

Current Medical Research and Opinion


Additional Info

Current Medical Research and Opinion
Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting
Curr Med Res Opin 2022 May 13;[EPub Ahead of Print], GL Price, L Sudharshan, P Ryan, J Rajkumar, KM Sheffield, E Nash Smyth, C Morato Guimaraes, S Rybowski, G Cuyun Carter, WG Gathirua-Mwangi, YJ Huang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading